Stephens Inc. Starts Harvard Bioscience with 'Buy'

Analyst John Sullivan says recent acquisitions have improved the company's competitive position

Stephens Inc. initiated coverage of Harvard Bioscience (HBIO ) with a buy recommendation, and set a $15 price target on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.